Edgewise’s HCM Candidate May Provide Advantages Over BMS’s Camzyos

 
• By Joseph Haas
  
Edgewise hopes to take on Bristol in HCM with a cardiac sarcomere modulator (Shutterstock)

More from Strategy

More from Therapy Areas